Amgen disclosed that its 52‑week extension study of the obesity drug MariTide confirmed sustained weight loss, with the majority of participants maintaining the reductions achieved in the core Phase 2 trial.
The extension data showed that patients continued to lose weight over the study period, with safety outcomes consistent with the earlier phase: gastrointestinal side effects were mild and transient, and discontinuation rates remained low. In the core Phase 2 study, MariTide produced up to 20% weight loss in non‑diabetic patients and 17% in those with type 2 diabetes, and the extension results support that level of efficacy over a longer period.
A second mid‑stage trial in patients with type 2 diabetes reported significant reductions in HbA1c and body weight, underscoring the drug’s metabolic benefits. The magnitude of the HbA1c decline was comparable to that seen with leading GLP‑1 therapies, while the weight loss remained robust, reinforcing MariTide’s potential to address both obesity and diabetes.
From a commercial perspective, the ability to maintain weight loss with a once‑monthly dosing schedule gives MariTide a distinct advantage over weekly injectables such as semaglutide (Wegovy) and tirzepatide (Zepbound). The data also support ongoing investigations into cardiovascular risk reduction, a broader indication that could expand the drug’s market reach. These findings strengthen Amgen’s pipeline and support the planned progression of MariTide into Phase 3 trials under the MARITIME program.
Amgen presented the core Phase 2 data at the J.P. Morgan Healthcare Conference on January 13, 2025. The company will share the extension study results at the 2026 conference, reinforcing its strategy to bring a monthly obesity treatment to market with proven efficacy and a favorable safety profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.